Table 3.
Comparison of the antibiotic treatment selections in ICU-treated and non-ICU-treated cases with or without IDSC
| Antibiotic selection | ICU treated (n = 42) | Non-ICU-treated IDSC+ (n = 83) | OR (95% CI) | p value a | Non-ICU-treated IDSC− (n = 63) | OR (95% CI) | p value b |
|---|---|---|---|---|---|---|---|
| Penicillin G as FA | 21 (50.0) | 49 (59.0) | 1.44 (0.68–3.04) | 0.337 | 13 (20.6) | 0.26 (0.11–0.61) | 0.002 |
| Iv-cephalosporins as FA | 5 (11.9) | 23 (27.7) | 2.84 (0.99–8.11) | 0.052 | 35 (55.6) | 9.25 (3.21–26.64) | < 0.001 |
| Piperacillin-tzb as FA | 6 (14.3) | 7 (8.4) | 0.55 (0.17–1.76) | 0.316 | 4 (6.3) | 0.41 (0.11–1.54) | 0.185 |
| Carbapenems as FA | 10 (23.8) | 3 (3.6) | 0.12 (0.031–0.47) | 0.002 | 7 (11.1) | 0.40 (0.14–1.15) | 0.090 |
| Clindamycin use in all combinations c | 36 (85.7) | 43 (51.8) | 0.18 (0.07–0.47) | < 0.001 | 8 (12.7) | 0.02 (0.01–0.08) | <0.001 |
IDSC infectious disease specialist consultation, ICU intensive care unit, FA first-line antibiotics
Data represents: No, (%) of the group
ap value: comparison of the groups ICU-treated and non-ICU-treated IDSC+ with logistic regression
bp value: comparison of the groups ICU-treated and non-ICU treated IDSC− with logistic regression
cClindamycin in all combinations includes all reported cases with clindamycin use (even as third antibiotic)